Bacillus clotting
Phase 3Small molecule
Bacillus clotting is one of 19 small molecule programs targeting Dyspepsia. It is currently in Phase 3.
1
Indications
3
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
25 competitors in Dyspepsia
#DrugCompanyPhaseTrials
1Prevacid
TakedaApproved
Buspar
Bristol-Myers SquibbApproved
Nexium
DDexcel Pharma Technologies Ltd.
Approved
Protonix
WWyeth-Lederle Vaccines
Approved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Resotran
TakedaApproved
Pepcid
KKenvue Brands
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Pulmicort
SSalix
Approved
Clostridium Butyricum
XXijing Hospital of Digestive Diseases
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Helicobacter Pylori Eradication2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bacillus clotting. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details